{"id":987503084,"date":"2026-07-15T15:56:03","date_gmt":"2026-07-15T15:56:03","guid":{"rendered":"https:\/\/boracdmo.com\/?p=987503084"},"modified":"2026-07-15T16:09:07","modified_gmt":"2026-07-15T16:09:07","slug":"bora-pharmaceuticals-and-insilico-medicine-partner-to-create-an-end-to-end-ai-integrated-drug-development-model","status":"publish","type":"post","link":"https:\/\/boracdmo.com\/bora-pharmaceuticals-and-insilico-medicine-partner-to-create-an-end-to-end-ai-integrated-drug-development-model\/","title":{"rendered":"Bora Pharmaceuticals and Insilico Medicine Partner to Create an End-to-End AI-Integrated Drug Development Model"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alliance combines Bora\u2019s global manufacturing quality and commercialization capabilities with Insilico\u2019s Pharma.AI platform<\/i><\/b><\/h3>\n\n

\n\tTaipei, Taiwan (July 15, 2026) <\/b>\u2013 Bora Pharmaceuticals Co., Ltd. (\u201cBora\u201d; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and Insilico Medicine (\u201cInsilico\u201d; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance to develop a true end-to-end AI solution to streamline drug development, ultimately helping to increase speed and probability for success, while lowering batch failures, human error, and investigation times.\n<\/p>\n\n\n

 <\/p>\n\n

\n\tThe alliance aims to integrate Insilico\u2019s novel Pharma.AI platform technology into Bora\u2019s formulation, CMC, scale-up, quality, regulatory execution, and commercial manufacturing capabilities to bring faster and more reliable execution to Bora\u2019s CDMO customers. Together, Bora and Insilico\u2019s partnership seeks to pioneer a next-generation innovation model that connects AI-enabled discovery with automation-driven development to deliver critical medicines to patients in need.\n<\/p>\n\n

 <\/p>\n\n

\n\t\u201cOur industry has made enormous progress applying AI to discovery. The next frontier is CMS, formulation, and manufacturing,\u201d said Bora Group CEO Bobby Sheng. \u201cIt\u2019s clear that the integration of AI is no longer merely an operational enhancement, it\u2019s a critical competitive differentiator. We\u2019re thrilled to form this alliance with Insilico to reach that next frontier and transform Bora into the undisputed industry leader in AI-integrated CDMO services.\u201d\n<\/p>\n\n

 <\/p>\n\n

\n\tBora and Insilico\u2019s alliance will provide the framework for multi-target collaboration across global discovery and development workflows. Over time, the alliance will explore opportunities to apply AI and automation-driven approaches across Bora\u2019s global capabilities to create an end-to-end process to streamline the next generation of biopharmaceutical innovation. If successful, the partnership will result in a scalable and repeatable model that can more efficiently advance promising drug candidates and establish a long-term growth platform through the development and commercialization of high-value proprietary assets \u2013 a result that could exceed a value of $2.5 billion and position Bora at the forefront of AI-enabled pharmaceutical development and manufacturing. \n<\/p>\n\n

 <\/p>\n\t\n

\n\t\u201cIn a short time from now, biopharmaceutical innovation is going to be completely AI-native, data-rich, and automation-driven,\u201d said Sheng. \u201cInsilico and its platforms have already demonstrated world-leading abilities to discover and design novel molecules and enhance efficiency in translating those molecules into high-quality development pipelines that deliver medicines to patients. Deploying these capabilities with Bora\u2019s existing global CDMO expertise creates the opportunity to create a fully integrated digital ecosystem spanning the entire development lifecycle.\u201d\n<\/p>\n\n

 <\/p>\n\n

\n\tFor Bora, the alliance demonstrates the company\u2019s commitment to delivering innovative solutions for customers. The integration of Insilico\u2019s AI technologies into the manufacturing process will lead to faster development, more reliable execution, and fewer batch failures and human errors, among other impacts designed to meet customer needs, and ultimately, make a greater impact for patients.\n<\/p>\n\n

 <\/p>\n\n

\n\t# # #\n<\/p>\n\n

 <\/p>\n\n

\n\tAbout Bora Pharmaceuticals<\/b>\n<\/p>\n

\n\tFounded in 2007, Bora Pharmaceuticals Co., Ltd. (\u201cBora\u201d or \u201cthe Company\u201d, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of \u201cContributing to Better Health All Over the World\u201d. Operating under a \u201cDual Engine\u201d model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients\u2019 quality of life. For more information, please visit www.bora-corp.com<\/a>.\n<\/p>\n\n

 <\/p>\n\n

\n\tAbout Insilico Medicine<\/b>\n<\/p>\n

\n\tInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.\n<\/p>\n\n

 <\/p>\n\n

\n\tBy integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com<\/a>.\n<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Alliance combines Bora\u2019s global manufacturing quality and commercialization capabilities with Insilico\u2019s Pharma.AI platform Taipei, Taiwan (July 15, 2026) \u2013 Bora Pharmaceuticals Co., Ltd. (\u201cBora\u201d; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and Insilico Medicine (\u201cInsilico\u201d; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance […]<\/p>\n","protected":false},"author":38,"featured_media":987503077,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[58],"tags":[],"class_list":["post-987503084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/comments?post=987503084"}],"version-history":[{"count":10,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503084\/revisions"}],"predecessor-version":[{"id":987503094,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503084\/revisions\/987503094"}],"wp:attachment":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media?parent=987503084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/categories?post=987503084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/tags?post=987503084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}